Exogenous galanin attenuates spatial memory impairment and decreases hippocampal beta-amyloid levels in rat model of Alzheimer's disease

References

• Oliveira AA Jr, Hodges HM. Alzheimer's disease and neural transplantation as prospective cell therapy. Curr Alzheimer Res 2005;2(1):79–95.
   PubMedGoogle Scholar
• Marin DB, Sewell MC, Schlechter A. Alzheimer's disease. Accurate and early diagnosis in the primary care setting. Geriatrics 2002;57(2):36–40; quiz 43.
   Google Scholar
• Sanz-Blasco S, Valero RA, Rodriguez-Crespo I, Mitochondrial Ca2+ overload underlies abeta oligomers neurotoxicity providing an unexpected mechanism of neuroprotection by NSAIDs. PLoS One 2008;3(7):e2718.
   PubMed Web of Science ®Google Scholar
• Oddo S, Caccamo A, Kitazawa M, Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 2003;24(8):1063–70.
   PubMedGoogle Scholar
• Benzing WC, Brady DR, Mufson EJ, Evidence that transmitter-containing dystrophic neurites precede those containing paired helical filaments within senile plaques in the entorhinal cortex of nondemented elderly and Alzheimer's disease patients. Brain Res 1993;619(1–2):55–68.
   PubMedGoogle Scholar
• Bell KF, Ducatenzeiler A, Ribeiro-da-Silva A, The amyloid pathology progresses in a neurotransmitter-specific manner. Neurobiol Aging 2006;27(11):1644–57.
   PubMedGoogle Scholar
• Perez SE, Dar S, Ikonomovic MD, Cholinergic forebrain degeneration in the APPswe/PS1DeltaE9 transgenic mouse. Neurobiol Dis 2007;28(1):3–15.
   PubMedGoogle Scholar
• Bierer LM, Haroutunian V, Gabriel S, Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem 1995;64(2):749–60.
   PubMedGoogle Scholar
• Selkoe DJ. Alzheimer's disease is a synaptic failure. Science; 2002; 298(5594):789–91.
   PubMed Web of Science ®Google Scholar
• Hokfelt T, Xu ZQ, Shi TJ, Galanin in ascending systems. Focus on coexistence with 5-hydroxytryptamine and noradrenaline. Ann NY Acad Sci 1998;863:252–63.
   PubMed Web of Science ®Google Scholar
• Chan-Palay V. Galanin hyperinnervates surviving neurons of the human basal nucleus of meynert in dementias of Alzheimer's and parkinson's disease: a hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia. J Comp Neurol 1988;273(4):543–57.
   PubMed Web of Science ®Google Scholar
• Chan-Palay V. Alterations in the locus coeruleus in dementias of Alzheimer's and parkinson's disease. Prog Brain Res 1991;88:625–30.
   PubMedGoogle Scholar
• Bowser R, Kordower JH, Mufson EJ. A confocal microscopic analysis of galaninergic hyperinnervation of cholinergic basal forebrain neurons in Alzheimer's disease. Brain Pathol 1997;7(2):723–30.
   PubMed Web of Science ®Google Scholar
• Mufson EJ, Cochran E, Benzing W, Galaninergic innervation of the cholinergic vertical limb of the diagonal band (Ch2) and bed nucleus of the stria terminalis in aging, Alzheimer's disease and down's syndrome. Dementia 1993;4(5):237–50.
   PubMedGoogle Scholar
• Elliott-Hunt CR, Marsh B, Bacon A, Galanin acts as a neuroprotective factor to the hippocampus. Proc Natl Acad Sci U S A 2004;101(14):5105–10.
   PubMed Web of Science ®Google Scholar
• Branchek TA, Smith KE, Gerald C, Galanin receptor subtypes. Trends Pharmacol Sci 2000;21(3):109–17.
   PubMedGoogle Scholar
• Webling KE, Runesson J, Bartfai T, Galanin receptors and ligands. Front Endocrinol (Lausanne) 2000;3:146.
   Google Scholar
• Yamaguchi Y, Miyashita H, Tsunekawa H, Effects of a novel cognitive enhancer, spiro[imidazo-[1,2-a]pyridine-3,2-indan]-2(3H)-one (ZSET1446), on learning impairments induced by amyloid-beta1–40 in the rat. J Pharmacol Exp Ther 2006;317(3):1079–87.
   PubMedGoogle Scholar
• Shin RW, Ogino K, Kondo A, Amyloid beta-protein (Abeta) 1–40 but not Abeta1–42 contributes to the experimental formation of alzheimer disease amyloid fibrils in rat brain. J Neurosci 1997;17(21):8187–93.
   PubMedGoogle Scholar
• Gabriel SM, Bierer LM, Davidson M, Galanin-like immunoreactivity is increased in the postmortem cerebral cortex from patients with Alzheimer's disease. J Neurochem 1994;62(4):1516–23.
   PubMed Web of Science ®Google Scholar
• Counts SE, Chen EY, Che S, Galanin fiber hypertrophy within the cholinergic nucleus basalis during the progression of Alzheimer's disease. Dement Geriatr Cogn Disord 2006;21(4):205–14.
   PubMed Web of Science ®Google Scholar
• Kowall NW, Beal MF. Galanin-like immunoreactivity is present in human substantia innominata and in senile plaques in Alzheimer's disease. Neurosci Lett 1989;98(1): 118–23.
   PubMedGoogle Scholar
• Dutar P, Lamour Y, Nicoll RA. Galanin blocks the slow cholinergic EPSP in CA1 pyramidal neurons from ventral hippocampus. Eur J Pharmacol 1989;164(2):355–60.
   PubMed Web of Science ®Google Scholar
• Fisone G, Wu CF, Consolo S, Galanin inhibits acetylcholine release in the ventral hippocampus of the rat: histochemical, autoradiographic, in vivo, and in vitro studies. Proc Natl Acad Sci U S A 1987;84(20):7339–43.
   PubMed Web of Science ®Google Scholar
• McDonald MP, Gleason TC, Robinson JK, Galanin inhibits performance on rodent memory tasks. Ann NY Acad Sci 1998;863:305–22.
   PubMed Web of Science ®Google Scholar
• Wrenn CC, Crawley JN. Pharmacological evidence supporting a role for galanin in cognition and affect. Prog Neuropsychopharmacol Biol Psychiatry 2001;25(1)283–99.
   PubMedGoogle Scholar
• Cui J, Chen Q, Yue X, Galanin protects against intracellular amyloid toxicity in human primary neurons. J Alzheimers Dis 2010;19(2):529–44.
   PubMedGoogle Scholar
• Cheng Y, Yu LC. Galanin protects -beta-induced neurotoxicity on primary cultured hippocampal neurons of rats. J Alzheimers Dis 2010;20(4):1143–57.
   PubMedGoogle Scholar
• Ding X, MacTavish D, Kar S, Galanin attenuates beta-amyloid (Abeta) toxicity in rat cholinergic basal forebrain neurons. Neurobiol Dis 2006;21(2):413–20.
   PubMed Web of Science ®Google Scholar
• Liu HX, Brumovsky P, Schmidt R, Receptor subtype-specific pronociceptive and analgesic actions of galanin in the spinal cord: selective actions via GalR1 and GalR2 receptors. Proc Natl Acad Sci U S A 2001;98(17):9960–4.
   PubMed Web of Science ®Google Scholar
• McMillan PJ, Peskind E, Raskind MA, Patterns of seizures, hippocampal injury and neurogenesis in three models of status epilepticus in galanin receptor type 1 (GalR1) knockout mice. Neuroscience 2004;128(2):431–41.
   PubMedGoogle Scholar
• Wrenn CC, Kinney JW, Marriott LK, Learning and memory performance in mice lacking the GAL-R1 subtype of galanin receptor. Eur J Neurosci 2004;19(5):1384–96.
   PubMedGoogle Scholar
• Kuteeva E, Wardi T, Lundstrom L, Differential role of galanin receptors in the regulation of depression-like behavior and monoamine/stress-related genes at the cell body level. Neuropsychopharmacology 2008;33(11):2573–85.
   PubMed Web of Science ®Google Scholar
• Mazarati A, Lu X, Shinmei S, Galanin type 2 receptors regulate neuronal survival, susceptibility to seizures and seizure-induced neurogenesis in the dentate gyrus. Eur J Neurosci 2004;19(12):3235–44.
   PubMed Web of Science ®Google Scholar
• Elliott-Hunt CR, Pope RJ, Vanderplank P, Activation of the galanin receptor 2 (GalR2) protects the hippocampus from neuronal damage. J Neurochem 2007;100(3):780–9.
   PubMed Web of Science ®Google Scholar
• Pirondi S, Fernandez M, Schmidt R, The galanin-R2 agonist AR-M1896 reduces glutamate toxicity in primary neural hippocampal cells. J Neurochem 2005;95(3):821–33.
   PubMedGoogle Scholar
• Wang S, Hashemi T, Fried S, , Differential intracellular signaling of the GalR1 and GalR2 galanin receptor subtypes. Biochemistry 1998;37(19):6711–7.
   PubMed Web of Science ®Google Scholar
• Johnson GV, Foley VG. Calpain-mediated proteolysis of microtubule-associated protein 2 (MAP-2) is inhibited by phosphorylation by cAMP-dependent protein kinase, but not by Ca2+/calmodulin-dependent protein kinase II. J Neurosci Res 1993;34(6):642–7.
   PubMedGoogle Scholar
• Pirondi S, Giuliani A, Del Vecchio G, The galanin receptor 2/3 agonist Gal2–11 protects the SN56 cells against beta-amyloid 25–35 toxicity. J Neurosci Res 2010; 88(5): 1064–73.
   PubMedGoogle Scholar